Clinical Edge Journal Scan

Antidiabetic drugs influence fracture risk in T2D


Key clinical point: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sulfonylureas (SUs) provide better protection against fractures in patients with type 2 diabetes (T2D) compared with thiazolidinedione (TZD). Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and dipeptidyl peptidase-4 inhibitors (DPP-4is) increase fracture risk vs. GLP1-RAs.

Major finding: Compared with TZD, the risk for fracture was significantly lower with GLP1-RA (risk ratio [RR], 0.50; 95% CI, 0.31-0.79) and sulfonylurea (RR, 0.56; 95% CI, 0.41-0.77); however, the risk was significantly higher with DPP-4i (RR, 1.76; 95% CI, 1.21-2.55) and SGLT-2i (RR, 1.50; 95% CI, 1.05-2.16) vs. GLP1-RA.

Study details: The data come from a meta-analysis of 161 trials including 191,361 patients with T2D who reported 2,916 fractures.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Tsai WH et al. Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract. 2022;192:110082 (Sep 16). Doi: 10.1016/j.diabres.2022.110082.

Recommended Reading

Insulin rationing common, ‘surprising’ even among privately insured
Type 2 Diabetes ICYMI
Drug repurposing ‘fast track’ to new medicines for obesity, diabetes
Type 2 Diabetes ICYMI
Diabetes becoming less potent risk factor for CVD events
Type 2 Diabetes ICYMI
Yoga and other mind-body work good for diabetes control
Type 2 Diabetes ICYMI
Tirzepatide vs. insulin glargine improves renal outcomes in T2D
Type 2 Diabetes ICYMI